PureTech Health PLC
PRTC18.090USD
+0.090+0.50%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
4.35BMarket Cap
100.88P/E TTM
More Details of PureTech Health PLC Company
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
PureTech Health PLC Info
Ticker SymbolPRTC
Company namePureTech Health PLC
IPO dateJun 19, 2015
CEOLyne (Robert)
Number of employees56
Security typeDepository Receipt
Fiscal year-endJun 19
Address6 Tide Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02210
Phone16174822333
Websitehttps://puretechhealth.com/
Ticker SymbolPRTC
IPO dateJun 19, 2015
CEOLyne (Robert)
Company Executives of PureTech Health PLC
Name
Name/Position
Position
Shareholding
Change
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Charles H. Sherwood, Ph.D.
Dr. Charles H. Sherwood, Ph.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Mr. Robert (Rob) Lyne
Mr. Robert (Rob) Lyne
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
Dr. Michele A. M. Holcomb, Ph.D.
Dr. Michele A. M. Holcomb, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Charles H. Sherwood, Ph.D.
Dr. Charles H. Sherwood, Ph.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 9
Updated: Sun, Nov 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Pentwater Capital Management LP
0.31%
Millennium Management LLC
0.07%
Diadema Partners LP
0.03%
Other
99.59%
Shareholders
Shareholders
Proportion
Pentwater Capital Management LP
0.31%
Millennium Management LLC
0.07%
Diadema Partners LP
0.03%
Other
99.59%
Shareholder Types
Shareholders
Proportion
Hedge Fund
0.42%
Other
99.58%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
19
102.96K
0.43%
-265.98K
2025Q3
20
111.77K
0.46%
-247.60K
2025Q2
15
335.52K
1.39%
-63.86K
2025Q1
14
393.56K
1.64%
-4.75K
2024Q4
14
374.87K
1.56%
+317.90K
2024Q3
13
30.04K
0.13%
-317.21K
2024Q2
12
323.23K
1.35%
+280.87K
2024Q1
9
25.15K
0.09%
-3.71K
2023Q4
10
11.40K
0.04%
-82.93K
2023Q3
12
84.27K
0.31%
-16.31K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Pentwater Capital Management LP
75.00K
0.31%
+25.00K
+50.00%
Sep 30, 2025
Millennium Management LLC
17.84K
0.07%
-6.02K
-25.22%
Sep 30, 2025
Diadema Partners LP
7.32K
0.03%
--
--
Sep 30, 2025
Persistent Asset Partners Limited
1.69K
0.01%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
770.00
0%
--
--
Nov 30, 2025
Dimensional Fund Advisors, L.P.
316.00
0%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
20.00
0%
--
--
Sep 30, 2025
Fidelity Management & Research Company LLC
--
0%
-1.28K
-100.00%
Sep 30, 2025
Atlantic Union Bankshares Corporation
--
0%
-115.00
-100.00%
Sep 30, 2025
Portolan Capital Management, L.L.C.
--
0%
-27.80K
-100.00%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
